Chemical formula: C₁₈₁H₂₉₁N₅₅O₅₁S₂ Molecular mass: 4,116.134 g/mol
Teriparatide (rhPTH(1-34)) is the active fragment (1-34) of endogenous human parathyroid hormone. Teriparatide is a bone formation agent to treat osteoporosis. The skeletal effects of teriparatide depend upon the pattern of systemic exposure.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| H05AA02 | Teriparatide | H Systemic hormonal preparations, excl. Sex hormones and insulins → H05 Calcium homeostasis → H05A Parathyroid hormones and analogues → H05AA Parathyroid hormones and analogues |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| TERROSA Solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| FORSTEO Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
| FORTEO Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Teriparatide is an active ingredient of these brands:
United States (US)Australia (AU)Brazil (BR)Ecuador (EC)Hong Kong (HK)New Zealand (NZ)Singapore (SG)South Africa (ZA)Turkey (TR)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
